A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Inclusion Criteria: * Adult subjects with CHC HCV genotype 1 with no previous treatment for CHC * 18 to 55 years of age * Weight between 40 and 125 kg * Previously documented CHC genotype 1 infection * Liver biopsy within 2 years of Screening with histology consistent with chronic hepatitis C and no evidence of bridging fibrosis or cirrhosis * Subject and subject's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug * Subjects must be willing to give written informed consent Exclusion Criteria: * Prior treatment for hepatitis C other than herbal remedies * HIV positive or known to be co-infected with hepatitis B * Medically significant gallbladder or hepatobiliary findings on Screening ultrasound * Use of any known significant inducers or substrates of CYP3A4 two weeks prior to start of study medications * Use of herbal supplements (Milk Thistle permitted) * Diabetic and hypertensive subjects with clinically significant ocular examination findings * Current moderate or severe depression * History of depression associated with any of the following: * Hospitalization for depression * Electroconvulsive therapy for depression. * Depression that resulted in a prolonged absence from work and/or significant disruption of daily functions * Suicidal or homicidal ideation and/or attempt * History of severe psychiatric disorders * Past history or current use of lithium * Clinical diagnosis of substance abuse of alcohol, intravenous drugs, inhalational (not including marijuana), psychotropics, narcotics, cocaine use, prescription or over-the-counter drugs within 5 years of Day 1 * Past or current use of opiate agonist substitution therapy * Any known pre-existing medical condition (CNS, cardiac, pulmonary, immune mediated) that could interfere with the subject's participation in and completion of the study * Active clinical gout within the last year * Hemoglobinopathy or coagulopathy * Myelodysplastic syndromes * Organ transplants other than cornea and hair * Poor venous access that precludes routine peripheral blood sampling or an indwelling venous catheter * Subjects with a history of gastric surgery (eg, stapling, banding, bypass) or subjects with a history of malabsorption disorders (eg, celiac sprue disease) * Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated basal cell carcinoma of the skin). Subjects under evaluation for malignancy are not eligible. * Subjects who are pregnant or nursing * Subjects who intend to become pregnant during the study period * Male subjects with partners who are, or intend to become, pregnant during the study period